X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DB-1305 (BNT325) is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the TROP2. It is being evaluated in phase 1/2 clinical trials for the treatment of patients with platinum-resistant ovarian epithelial cancer, fallopian tube cancer.
Lead Product(s): BNT325
Therapeutic Area: Oncology Product Name: DB-1305
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: BioNTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
BNT323 (DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2. It is under phase 3 clinical development for the treatment of metastatic breast cancer.
Lead Product(s): DB-1303
Therapeutic Area: Oncology Product Name: BNT323
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
BNT323 (DB-1303) is a next-generation Topoisomerase 1 inhibitor, ADC candidate targeting HER2, a cell surface protein. It is under phase 1/2 clinical development for the treatment of HER2-expressing advanced endometrial cancer.
Lead Product(s): DB-1303
Therapeutic Area: Oncology Product Name: BNT323
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: BioNTech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
Under the expanded collaboration, BioNTech will develop, manufacture and commercialize DB-1305, a third generation Trop2 ADC molecule built from DualityBio's proprietary DITAC platform, globally, excluding Mainland China, Hong Kong and Macau Special Administrative Region.
Lead Product(s): DB-1303
Therapeutic Area: Oncology Product Name: DB-1303
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: $1,670.0 million Upfront Cash: $170.0 million
Deal Type: Expanded Collaboration August 07, 2023
Details:
Under the agreement, BeiGene will acquire an exclusive option for a global clinical and commercial license to DB-1312, an investigational, preclinical antibody-drug conjugate therapy for solid tumors and DualityBio will continue preclinical research and support IND filing.
Lead Product(s): DB-1312
Therapeutic Area: Oncology Product Name: DB-1312
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: $1,300.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 10, 2023
Details:
Under the agreement, new targets will be evaluated with Duality’s linker-payload platform, designed to generate ADCs with superior safety profiles, sustainable payload delivery and release in tumors, and efficient bystander killing of antigen low and negative cells.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Adcendo
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 30, 2023
Details:
Under the collaboration, BioNTech will gain access to DualityBio’s DB-1303, which is a topoisomerase-1 inhibitor-based ADC directed against HER2, a target that is overexpressed in a variety of cancers. The DB-1303 program received Fast Track designation from the U.S. FDA.
Lead Product(s): DB-1303
Therapeutic Area: Oncology Product Name: DB-1303
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: $1,670.0 million Upfront Cash: $170.0 million
Deal Type: Collaboration April 03, 2023
Details:
DB-1303, a 3rd generation HER2 ADC molecule built from DITAC platform, exhibited potent antitumor activity in both HER2 positive and HER2 low tumor models with superior efficacy, safety and expanded therapeutic window.
Lead Product(s): DB-1303
Therapeutic Area: Oncology Product Name: DB-1303
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
Antibody Drug Conjugates (ADC) are a class of highly potent biopharmaceutical drug composed of a targeting antibody linked to a biologically active drug or cytotoxic compound. uPARAP is a novel cancer target overexpressed on the cell surface of mesenchymal cancers.
Lead Product(s): Antibody-drug Conjugate-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Adcendo
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
